Spero Therapeutics Strengthens Leadership Team to Advance Immunology Pipeline

Spero Therapeutics appointed Amy Rock, Ph.D., as Chief Regulatory and Quality Officer and Dae Gon Ha, Ph.D., as SVP of Corporate Development, strengthening its team around the SP001 immunology program. Chief Operating Officer Timothy Keutzer will retire after 11 years, effective December 31, 2026, with his responsibilities absorbed by existing executives rather than a named successor. Dr. Rock joins from Vir Biotechnology where she led global regulatory sciences, and Dr.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.